Xiaohan Liu

Xiaohan Liu

Auto-generated profile, based on publicly available information

Xiaohan Liu

School of Biology, Food and Environment, Hefei University, Hefei 230601, P. R. China

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
19 February 2025 in Molecules
Verified
Journal Article
Open access
PDF file
XLXiaohan Liu
Xiaohan Liu
JPJian Pei
Jian Pei
JLJiahui Li
Jiahui Li
HZHuiyu Zhu
Huiyu Zhu
XZXiaoyu Zheng
Xiaoyu Zheng
LCLiuzeng Chen
Liuzeng Chen
Resveratrol, a naturally occurring phenolic stilbene molecule, has been intensively researched for its anti-inflammatory, anticancer, antioxidant, antibacterial, and neuroprotective properties. However, due to its limited absorption and probable hepatotoxicity, it is difficult to employ directly as a medication, limiting its therapeutic applicability. Over the last five years, numerous structural changes in resveratrol have been widely studied, resulting in considerable improvements in pharmacological activity and drug availability. This work reviews the biological activities and structure–activity relationships (SARs) of resveratrol derivatives, with the goal of providing useful insights for the discovery of new resveratrol derivatives.

21 February 2025 in RSC Medicinal Chemistry
Verified
Journal Article
Closed access
PDF file
XLXiaohan Liu
Xiaohan Liu
BZBin Zhou
Bin Zhou
YCYan Chen
Yan Chen
JLJinyuan Lin
Jinyuan Lin
CSChenwen Shao
Chenwen Shao
YQYong Qian
Yong Qian
It has been reported that 17β-HSD10 plays a key role in Alzheimer's disease. Here, a total of 44 2-phenyl-1H-benzo[d]imidazole derivatives were designed and synthesized as novel 17β-HSD10 inhibitors based on rational design and SAR studies. Among them, compound 33 (N-(4-(1,4,6-trimethyl-1H-benzo[d] imidazol-2-yl)phenyl)cyclohexanecarboxamide) showed high inhibitory efficacy (17β-HSD10 IC50 = 1.65 ± 0.55 μM) and low toxicity (HepaRG IC50 >100 μM). The Morris water maze experiment revealed that compound 33 could alleviate cognitive impairment induced by scopolamine in mice. This study facilitates the further development of more potent 17β-HSD10 inhibitors for the treatment of Alzheimer's disease.